Evidence map›Paper›PMID 28427285›Full record

ArticleThe American journal of psychiatry2017

Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels.

Peter J Schmidt, Pedro E Martinez, Lynnette K Nieman, Deloris E Koziol, Karla D Thompson, Linda Schenkel, Paul G Wakim, David R Rubinow

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04225221 (Ovarian Hormones, Reward Response, and Binge Eating in Bulimia Nervosa), which is not on this map. Cited by 109 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 6 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04225221 phase2completednot on this mapstarted 2020, after this paper: background citation

Ovarian Hormones, Reward Response, and Binge Eating in Bulimia Nervosa: An Experimental Design

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2020 to 2022Enrolled10ConditionsBulimia NervosaArmsEstradiol, Micronized progesterone, Leuprolide Acetate, Placebo Oral Capsule
3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 6 syntheses or guidelines pooled it, 198 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Peter J SchmidtFrom the Behavioral Endocrinology Branch, NIMH, Bethesda, Md.; the Intramural Research Program on Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Md.; the Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, Md.,; and the Department of Psychiatry, University of North Carolina, Chapel Hill, N.C.
Pedro E MartinezFrom the Behavioral Endocrinology Branch, NIMH, Bethesda, Md.; the Intramural Research Program on Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Md.; the Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, Md.,; and the Department of Psychiatry, University of North Carolina, Chapel Hill, N.C.
Lynnette K NiemanFrom the Behavioral Endocrinology Branch, NIMH, Bethesda, Md.; the Intramural Research Program on Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Md.; the Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, Md.,; and the Department of Psychiatry, University of North Carolina, Chapel Hill, N.C.
Deloris E KoziolFrom the Behavioral Endocrinology Branch, NIMH, Bethesda, Md.; the Intramural Research Program on Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Md.; the Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, Md.,; and the Department of Psychiatry, University of North Carolina, Chapel Hill, N.C.
Karla D ThompsonFrom the Behavioral Endocrinology Branch, NIMH, Bethesda, Md.; the Intramural Research Program on Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Md.; the Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, Md.,; and the Department of Psychiatry, University of North Carolina, Chapel Hill, N.C.
Linda SchenkelFrom the Behavioral Endocrinology Branch, NIMH, Bethesda, Md.; the Intramural Research Program on Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Md.; the Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, Md.,; and the Department of Psychiatry, University of North Carolina, Chapel Hill, N.C.
Paul G WakimFrom the Behavioral Endocrinology Branch, NIMH, Bethesda, Md.; the Intramural Research Program on Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Md.; the Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, Md.,; and the Department of Psychiatry, University of North Carolina, Chapel Hill, N.C.
David R RubinowFrom the Behavioral Endocrinology Branch, NIMH, Bethesda, Md.; the Intramural Research Program on Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Md.; the Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, Md.,; and the Department of Psychiatry, University of North Carolina, Chapel Hill, N.C.
Eunice Kennedy Shriver National Institute of Child Health and Human Development · US

Funding

Reproductive Endocrine Related Mood Disorders-Differential SensitivityZIAMH002865 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI SCHMIDT, PETER · 2009 to 2025
$11.9M
Reproductive Endocrine Related Mood Disorders-Differential SensitivityZ01MH002865 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI SCHMIDT, PETER J · 2006 to 2008
$1.6M
Steroid Hormone Action In Female ReproductionZIADK075118 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI NIEMAN, LYNNETTE · 2016 to 2021
$126k
Intramural NIH HHS Z01 MH002865
6 · The paper itself

Abstract

objectivePremenstrual dysphoric disorder (PMDD) symptoms are eliminated by ovarian suppression and stimulated by administration of ovarian steroids, yet they appear with ovarian steroid levels indistinguishable from those in women without PMDD. Thus, symptoms could be precipitated either by an acute change in ovarian steroid levels or by stable levels above a critical threshold playing a permissive role in expression of an underlying infradian affective "pacemaker." The authors attempted to determine which condition triggers PMDD symptoms.

methodThe study included 22 women with PMDD, ages 30 to 50 years. Twelve women who experienced symptom remission after 2-3 months of GnRH agonist-induced ovarian suppression (leuprolide) then received 1 month of single-blind (participant only) placebo and then 3 months of continuous combined estradiol/progesterone. Primary outcome measures were the Rating for Premenstrual Tension observer and self-ratings completed every 2 weeks during clinic visits. Multivariate repeated-measure ANOVA for mixed models was employed.

resultsBoth self- and observer-rated scores on the Rating for Premenstrual Tension were significantly increased (more symptomatic) during the first month of combined estradiol/progesterone compared with the last month of leuprolide alone, the placebo month, and the second and third months of estradiol/progesterone. There were no significant differences in symptom severity between the last month of leuprolide alone, placebo month, or second and third months of estradiol/progesterone. Finally, the Rating for Premenstrual Tension scores in the second and third estradiol/progesterone months did not significantly differ.

conclusionsThe findings demonstrate that the change in estradiol/progesterone levels from low to high, and not the steady-state level, was associated with onset of PMDD symptoms. Therapeutic efforts to modulate the change in steroid levels proximate to ovulation merit further study.

Indexed as

AdultAffectEstradiolEstrogensFemaleFertility Agents, FemaleGonadotropin-Releasing HormoneHumansLeuprolideMiddle AgedMultivariate AnalysisOvulation InhibitionPremenstrual Dysphoric DisorderProgesteroneProgestinsSingle-Blind MethodEstradiolEstrogensFertility Agents, FemaleGonadotropin-Releasing HormoneLeuprolideProgesteroneProgestinsestradiolPremenstrual Syndromeprogesterone

Identifiers

PMID28427285
PMCPMC5624833
OpenAlexW2605853539

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.